Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema
Recruitment status was Recruiting
Efficacy duration of triamcinolone acetonide (steroid) for treatment of diabetic macular edema. Furthermore, dosage dependency of triamcinolone acetonide comparing a high dosage versus a low dosage.
Diabetic Macular Edema
Drug: Intravitreal injection (triamcinolone acetonide)
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
|Official Title:||Dosage Dependency of Intravitreal Triamcinolone Acetonide for Treatment of Diabetic Macular Edema|
- Visual acuity, no of treatments, duration of efficacy [ Time Frame: 12 months ]
- intraocular pressure, retinal thickness [ Time Frame: 12 months ]
|Study Start Date:||July 2006|
|Estimated Study Completion Date:||December 2007|
Patients with diabetic retinopathy suffer from visual acuity loss caused by diabetic macular edema. Intravitreal injected Triamcinolone Acetonide (steroid) reduces macular edema and increases visual acuity. The duration of its effect is however limited. Therefore, several injections are necessary.
In this study a dosage dependency of triamcinolone acetonide (high dosage vs low dosage) is performed. The primary outcome parameters are the number of treatments and the efficacy of each injection.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00476918
|Contact: Ulrich HM Spandau, PhD MDfirstname.lastname@example.org|
|Contact: Anne Wickenhaeuser, MD||+496213832242||anne.wickenhäuser@augen.ma.uni-heidelberg.de|
|Dep of Ophthalmology, University of Mannheim||Recruiting|
|Mannheim, Germany, 68167|
|Principal Investigator: Ulrich HM Spandau, PhD MD|
|Study Director:||Jost Jonas, PhD MD||Dep of Ophthalmology, University of Mannheim|